

Soon June Bae

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2400638/publications.pdf>

Version: 2024-02-01

50
papers

439
citations

840119

11
h-index

887659

17
g-index

55
all docs

55
docs citations

55
times ranked

643
citing authors

#	ARTICLE	IF	CITATIONS
1	Comparison of tumor-infiltrating lymphocytes of breast cancer in core needle biopsies and resected specimens: a retrospective analysis. <i>Breast Cancer Research and Treatment</i> , 2018, 171, 295-302.	1.1	40
2	Associations between absolute neutrophil count and lymphocyte-predominant breast cancer. <i>Breast</i> , 2020, 50, 141-148.	0.9	30
3	High A20 expression negatively impacts survival in patients with breast cancer. <i>PLoS ONE</i> , 2019, 14, e0221721.	1.1	24
4	Comparison of complications according to incision types in nipple-sparing mastectomy and immediate reconstruction. <i>Breast</i> , 2020, 53, 85-91.	0.9	24
5	Comparisons of tumor-infiltrating lymphocyte levels and the 21-gene recurrence score in ER-positive/HER2-negative breast cancer. <i>BMC Cancer</i> , 2018, 18, 320.	1.1	22
6	Ex Vivo Shear-Wave Elastography of Axillary Lymph Nodes to Predict Nodal Metastasis in Patients with Primary Breast Cancer. <i>Journal of Breast Cancer</i> , 2018, 21, 190.	0.8	19
7	Radiotherapy-Induced High Neutrophil-to-Lymphocyte Ratio is a Negative Prognostic Factor in Patients with Breast Cancer. <i>Cancers</i> , 2020, 12, 1896.	1.7	18
8	Immediate Breast Reconstruction Does Not Have a Clinically Significant Impact on Adjuvant Treatment Delay and Subsequent Survival Outcomes. <i>Journal of Breast Cancer</i> , 2019, 22, 109.	0.8	17
9	Prognostic value of neutrophil-to-lymphocyte ratio in human epidermal growth factor receptor 2-negative breast cancer patients who received neoadjuvant chemotherapy. <i>Scientific Reports</i> , 2020, 10, 13078.	1.6	17
10	Body mass index and absolute lymphocyte count predict disease-free survival in Korean breast cancer patients. <i>British Journal of Cancer</i> , 2021, 125, 119-125.	2.9	15
11	Low PR in ER(+)/HER2(âˆ“) breast cancer: high rates of TP53 mutation and high SUV. <i>Endocrine-Related Cancer</i> , 2019, 26, 177-185.	1.6	15
12	A nomogram constructed using intraoperative ex vivo shear-wave elastography precisely predicts metastasis of sentinel lymph nodes in breast cancer. <i>European Radiology</i> , 2020, 30, 789-797.	2.3	14
13	Local Treatment in Addition to Endocrine Therapy in Hormone Receptor-Positive and HER2-Negative Oligometastatic Breast Cancer Patients: A Retrospective Multicenter Analysis. <i>Breast Care</i> , 2020, 15, 408-414.	0.8	13
14	Clinical and genomic assessment of PD-L1 SP142 expression in triple-negative breast cancer. <i>Breast Cancer Research and Treatment</i> , 2021, 188, 165-178.	1.1	13
15	A phase II study investigating the acute toxicity of targeted intraoperative radiotherapy as tumor-bed boost plus whole breast irradiation after breast-conserving surgery in Korean patients. <i>Breast Cancer Research and Treatment</i> , 2019, 174, 157-163.	1.1	12
16	Genomic Signature of the Standardized Uptake Value in 18F-Fluorodeoxyglucose Positron Emission Tomography in Breast Cancer. <i>Cancers</i> , 2020, 12, 497.	1.7	12
17	High Nuclear Expression of Yes-Associated Protein 1 Correlates With Metastasis in Patients With Breast Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 609743.	1.3	11
18	Real-World Clinical Outcomes of Biosimilar Trastuzumab (CT-P6) in HER2-Positive Early-Stage and Metastatic Breast Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 689587.	1.3	11

#	ARTICLE	IF	CITATIONS
19	Validation of Clinical Treatment Score post-5Âyears (CTS5) risk stratification in premenopausal breast cancer patients and Ki-67 labelling index. <i>Scientific Reports</i> , 2020, 10, 16850.	1.6	9
20	Primary endocrine resistance of ER+ breast cancer with ESR1 mutations interrogated by droplet digital PCR. <i>Npj Breast Cancer</i> , 2022, 8, 58.	2.3	9
21	Measuring Tumor Extent Based on Subtypes Using Magnetic Resonance Imaging: Radiologic-Pathologic Discordance and High Positive Margin Rates in Breast Cancer. <i>Journal of Breast Cancer</i> , 2019, 22, 453.	0.8	8
22	Repeat Sentinel Lymph Node Biopsy for Ipsilateral Breast Tumor Recurrence After Breast Conserving Surgery With Sentinel Lymph Node Biopsy: Pooled Analysis Using Data From a Systematic Review and Two Institutions. <i>Frontiers in Oncology</i> , 2020, 10, 518568.	1.3	8
23	Diagnostic Accuracy of Nonmass Enhancement at Breast MRI in Predicting Tumor Involvement of the Nipple: A Prospective Study in a Single Institution. <i>Radiology</i> , 2021, 301, 47-56.	3.6	8
24	PD-L1 expression evaluated by 22C3 antibody is a better prognostic marker than SP142/SP263 antibodies in breast cancer patients after resection. <i>Scientific Reports</i> , 2021, 11, 19555.	1.6	8
25	Significance of Non-Mass Enhancement in the Subareolar Region on Preoperative Breast Magnetic Resonance Imaging for Nipple-Sparing Mastectomy. <i>Clinical Breast Cancer</i> , 2020, 20, e458-e468.	1.1	7
26	Axillary response according to neoadjuvant single or dual human epidermal growth factor receptor 2 (<scp>HER2</scp>) blockade in clinically nodeâ€positive, <scp>HER2</scp>â€positive breast cancer. <i>International Journal of Cancer</i> , 2021, 149, 1585-1592.	2.3	6
27	The Impact of Post-Mastectomy Radiotherapy on Survival Outcomes in Breast Cancer Patients Who Underwent Neoadjuvant Chemotherapy. <i>Cancers</i> , 2021, 13, 6205.	1.7	6
28	Clinical Features of Breast Cancer in South Korean Patients with Germline <i>TP53</i> Gene Mutations. <i>Journal of Breast Cancer</i> , 2021, 24, 175.	0.8	5
29	Relationship of the standard uptake value of 18F-FDG-PET-CT with tumor-infiltrating lymphocytes in breast tumors measuringâ€%â%â€%1Åcm. <i>Scientific Reports</i> , 2021, 11, 12046.	1.6	5
30	From cadaveric and animal studies to the clinical reality of robotic mastectomy: a feasibility report of training program. <i>Scientific Reports</i> , 2021, 11, 21032.	1.6	5
31	Metastasis Risk Assessment Using BAG2 Expression by Cancer-Associated Fibroblast and Tumor Cells in Patients with Breast Cancer. <i>Cancers</i> , 2021, 13, 4654.	1.7	4
32	Association between TP53 mutation and high 21-gene recurrence score in estrogen receptor-positive/HER2-negative breast cancer. <i>Npj Breast Cancer</i> , 2022, 8, 19.	2.3	4
33	Added value of abbreviated breast magnetic resonance imaging for assessing suspicious microcalcification on screening mammographyâ€”a prospective study. <i>European Radiology</i> , 2022, 32, 815-821.	2.3	3
34	Chemosensitivity to doxorubicin of ER-positive/HER2-negative breast cancers with high 21-gene recurrence score: A study based on in vitro chemoresponse assay. <i>PLoS ONE</i> , 2017, 12, e0187679.	1.1	3
35	Comparison of resection margin status after single or double radiopaque marker insertion for tumor localization in breast cancer patients receiving neoadjuvant chemotherapy. <i>Breast Cancer Research and Treatment</i> , 2020, 184, 797-803.	1.1	2
36	The association between the expression of nuclear Yes-associated protein 1 (YAP1) and p53 protein expression profile in breast cancer patients. <i>PLoS ONE</i> , 2021, 16, e0250986.	1.1	2

#	ARTICLE	IF	CITATIONS
37	Application of the 21-Gene Recurrence Score in Patients with Early HR-Positive/HER2-Negative Breast Cancer: Chemotherapy and Survival Rate According to Clinical Risk. <i>Cancers</i> , 2021, 13, 4003.	1.7	2
38	A neutrophil to lymphocyte ratio is predictive of response to neoadjuvant HER2-targeted therapies in the patients with HER2-positive breast cancer.. <i>Journal of Clinical Oncology</i> , 2019, 37, 587-587.	0.8	2
39	RT-induced dynamic changes in the lymphocyte-to-monocyte ratio in patients with breast cancer indicate poor prognosis. <i>Breast Cancer Research and Treatment</i> , 2022, 193, 637.	1.1	2
40	Anaemia and pathologic complete response rate according to carboplatin dose in <scp>HER2</scp>+ breast cancer treated with neoadjuvant <scp>TCHP</scp>. <i>Cancer Medicine</i> , 2023, 12, 1409-1417.	1.3	2
41	A gene expression signature of <i>FOXM1-AURKB-CDKN1A</i> to recapitulate molecular characteristics of standardized uptake value of ¹⁸F-FDG-PET in breast cancer.. <i>Journal of Clinical Oncology</i> , 2018, 36, 12105-12105.	0.8	1
42	SP142 PD-L1 Assays in Multiple Samples from the Same Patients with Early or Advanced Triple-Negative Breast Cancer. <i>Cancers</i> , 2022, 14, 3042.	1.7	1
43	The Role of Bile Duct Probe for Bile Duct Division during Donor Right Hemihepatectomy. <i>The Journal of the Korean Society for Transplantation</i> , 2016, 30, 172.	0.2	0
44	Abstract PS10-02: A good prognosis of endocrine-dependent tumors among residual invasive cancer after anti-HER2 therapy: CALGB 40601 (Alliance) and validation studies. , 2021, , .		0
45	Abstract PS13-13: The value of shear-wave elastography for prediction of treatment response to neoadjuvant chemotherapy in patients with breast cancer. , 2021, , .		0
46	Abstract P4-05-08: 18F-FDG uptake of visceral adipose tissue on preoperative PET/CT as a predictive marker for breast cancer recurrence. <i>Cancer Research</i> , 2022, 82, P4-05-08-P4-05-08.	0.4	0
47	Abstract P2-12-13: Pathologic complete response rate according to the carboplatin dose in patients with non-metastatic HER2+ breast cancer treated with neoadjuvant docetaxel/carboplatin/trastuzumab/pertuzumab (TCHP). <i>Cancer Research</i> , 2022, 82, P2-12-13-P2-12-13.	0.4	0
48	Abstract P1-08-11: Clinical relevance of host immunity in patients with breast cancer who received neoadjuvant chemotherapy. <i>Cancer Research</i> , 2022, 82, P1-08-11-P1-08-11.	0.4	0
49	Abstract P3-12-14: Attenuated negative prognostic effect of progesterone receptor negativity in postmenopausal ER+ breast cancer with normal BMI (<25): A nation-wide study in Korean Breast Cancer Society and the institutional cohort. <i>Cancer Research</i> , 2022, 82, P3-12-14-P3-12-14.	0.4	0
50	Breast density reduction as a predictor for prognosis in premenopausal women with hormone receptor- positive breast cancer: A retrospective analysis of the ASTRRA study.. <i>Journal of Clinical Oncology</i> , 2022, 40, 531-531.	0.8	0